LAB FARMACEUT ERFO risk profile
21 Normal where most of the sector sits
Measured 1 September 2026 from ERFO.MI's filed statements. Recomputed nightly.
21 (Normal), driven by Cash conversion at 65, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 61 | Stretched | Stable | One-year price volatility — 39.5% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 65 | Stretched | Stable | Capital spending against operating cash — 2.79x |
| Leverage and coverage | 8 | Contained | Stable | Current ratio — 1.91x |
| Competitive position | 6 | Contained | Stable | Operating-margin gap against peers — +21.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Consumer Defensive companies with a risk reading
Walmart Inc 43Costco Wholesale Corp 40Coca-Cola Company 30Procter & Gamble Company 34Philip Morris International Inc 24Nestle S.A. 45Nestlé S.A 45L'Oréal S.A. 32PepsiCo Inc 43Anheuser-Busch InBev SA/NV 35Unilever plc 42Unilever PLC 42
Financials, valuation and price history for LAB FARMACEUT ERFO